241 related articles for article (PubMed ID: 10626788)
41. E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6.
Zheng L; Ding H; Lu Z; Li Y; Pan Y; Ning T; Ke Y
Genes Cells; 2008 Mar; 13(3):285-94. PubMed ID: 18298802
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Mantovani F; Banks L
Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
[TBL] [Abstract][Full Text] [Related]
43. Human papillomavirus E6 regulates the cytoskeleton dynamics of keratinocytes through targeted degradation of p53.
Cooper B; Brimer N; Vande Pol SB
J Virol; 2007 Nov; 81(22):12675-9. PubMed ID: 17804489
[TBL] [Abstract][Full Text] [Related]
44. Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6.
Gardiol D; Banks L
J Gen Virol; 1998 Aug; 79 ( Pt 8)():1963-70. PubMed ID: 9714244
[TBL] [Abstract][Full Text] [Related]
45. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
Honda R; Yasuda H
EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
[TBL] [Abstract][Full Text] [Related]
46. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.
Scheffner M; Huibregtse JM; Vierstra RD; Howley PM
Cell; 1993 Nov; 75(3):495-505. PubMed ID: 8221889
[TBL] [Abstract][Full Text] [Related]
47. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation.
Koumenis C; Alarcon R; Hammond E; Sutphin P; Hoffman W; Murphy M; Derr J; Taya Y; Lowe SW; Kastan M; Giaccia A
Mol Cell Biol; 2001 Feb; 21(4):1297-310. PubMed ID: 11158315
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of Bak-induced apoptosis by HPV-18 E6.
Thomas M; Banks L
Oncogene; 1998 Dec; 17(23):2943-54. PubMed ID: 9881696
[TBL] [Abstract][Full Text] [Related]
49. A ubiquitin variant-based affinity approach selectively identifies substrates of the ubiquitin ligase E6AP in complex with HPV-11 E6 or HPV-16 E6.
Ebner FA; Sailer C; Eichbichler D; Jansen J; Sladewska-Marquardt A; Stengel F; Scheffner M
J Biol Chem; 2020 Oct; 295(44):15070-15082. PubMed ID: 32855237
[TBL] [Abstract][Full Text] [Related]
50. Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6.
Lagrange M; Charbonnier S; Orfanoudakis G; Robinson P; Zanier K; Masson M; Lutz Y; Trave G; Weiss E; Deryckere F
J Gen Virol; 2005 Apr; 86(Pt 4):1001-1007. PubMed ID: 15784893
[TBL] [Abstract][Full Text] [Related]
51. Differential localization of HPV16 E6 splice products with E6-associated protein.
Vaeteewoottacharn K; Chamutpong S; Ponglikitmongkol M; Angeletti PC
Virol J; 2005 Jun; 2():50. PubMed ID: 15960845
[TBL] [Abstract][Full Text] [Related]
52. Identification of E6AP-independent degradation targets of HPV E6.
Vats A; Thatte J; Banks L
J Gen Virol; 2019 Dec; 100(12):1674-1679. PubMed ID: 31609195
[TBL] [Abstract][Full Text] [Related]
53. Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.
Heessen S; Leonchiks A; Issaeva N; Sharipo A; Selivanova G; Masucci MG; Dantuma NP
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1532-7. PubMed ID: 11805282
[TBL] [Abstract][Full Text] [Related]
54. The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19(ARF).
Seavey SE; Holubar M; Saucedo LJ; Perry ME
J Virol; 1999 Sep; 73(9):7590-8. PubMed ID: 10438849
[TBL] [Abstract][Full Text] [Related]
55. A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells.
Allen KL; Tschantz DR; Awad KS; Lynch WP; DeLucia AL
Mol Carcinog; 2007 Jul; 46(7):564-75. PubMed ID: 17393435
[TBL] [Abstract][Full Text] [Related]
56. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function.
Lu W; Pochampally R; Chen L; Traidej M; Wang Y; Chen J
Oncogene; 2000 Jan; 19(2):232-40. PubMed ID: 10645001
[TBL] [Abstract][Full Text] [Related]
57. A Cu
Kumar A; Kuhn LT; Balbach J
FEBS J; 2018 Aug; 285(16):3013-3025. PubMed ID: 29931810
[TBL] [Abstract][Full Text] [Related]
58. Defining the minimal requirements for papilloma viral E6-mediated inhibition of human p53 activity in fission yeast.
Waddell S; Jenkins JR
Oncogene; 1998 Apr; 16(13):1759-65. PubMed ID: 9582024
[TBL] [Abstract][Full Text] [Related]
59. A small-molecule inhibitor of MDMX suppresses cervical cancer cells via the inhibition of E6-E6AP-p53 axis.
Zhang J; Yu G; Yang Y; Wang Y; Guo M; Yin Q; Yan C; Tian J; Fu F; Wang H
Pharmacol Res; 2022 Mar; 177():106128. PubMed ID: 35150860
[TBL] [Abstract][Full Text] [Related]
60. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2.
Ito A; Lai CH; Zhao X; Saito S; Hamilton MH; Appella E; Yao TP
EMBO J; 2001 Mar; 20(6):1331-40. PubMed ID: 11250899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
